While our study stands as the inaugural examination of the impact of SGLT2 inhibitors on echocardiographic variables of cardiac remodeling in traditionally underrepresented populations with diabetes, it is not without limitations. The gene discussed is SLC5A2; the disease is diabetes mellitus.